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PegvisomantMono-therapy using long-acting somatostatin analogues and surgery cannot provide optimal biochemical
control in a large proportion of patients with acromegaly. This results in increased mortality, poor control of
signs and symptoms of disease and decreased quality of life. Combined treatmentwith somatostatin analogues
and pegvisomant (a growth-hormone-receptor antagonist) seems to be an attractive option. Combination
treatment is highly effective at normalising the level of insulin-like growth factor 1 in over 90% of patients and
has a favourable effect on quality of life in those with biochemically controlled acromegaly. Moreover,
combination therapy with somatostatin analogues results in a clinically relevant decrease in tumour size in
about 20% of patients, whereas pegvisomant (PEG-V) mono-therapy does not decrease pituitary tumour size.
Transient elevations in the levels of transaminases are the main adverse effects of combination treatment,
which occur in about 11–15% of patients.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
Acromegaly is a rare disease, which is often caused by a growth
hormone (GH) secreting benign pituitary tumour resulting in a reduced
life expectancy [1]. Treatment of this disease should improve life
expectancy, reduce signs and symptoms and thereby increase the
quality of life (QoL). These goals should be achievable by normalising
insulin-like growth factor 1 (IGF1) and GH. To date, treatment
modalities mainly focus on the normalisation of IGF1 by targeting GH
production or GH action.
Depending on the size and localisation of the pituitary adenoma
and the patients' characteristics a treatment modality should be
chosen. However, more than 75% of these pituitary adenomas are
macroadenomas, which often extend dorsally of the suprasellar
region or laterally to the cavernous sinus [1]. In a minority of cases
microadenomas are found. Surgery cure rates of microadenomas
up to 80% are reported in highly specialised centres [2]. However, in
other centres, cure rates of less than 40% are reported [3]. The cure
rates for macroadenomas are even worse [3].
The available long-acting somatostatin analogues (LA-SRIF) are
reported to have efﬁcacy rates in normalising IGF1 and GH of about 50%nsultant for Novartis Pharma,
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vier OA license. [2]. The reported efﬁcacy rates for LA-SRIF are better than those for
surgical outcome in patients withmacroadenomas andmicroadenomas
in less specialised centres. However, compared with pegvisomant
(PEG-V), efﬁcacy rates for LA-SRIF treatment are lower. Combined with
LA-SRIF or as mono-therapy, PEG-V has an efﬁcacy rate in normalising
serum IGF1 levels of more than 90%, but during combined treatment a
lower cumulative dose of PEG-V seems to be necessary [4–9]. Reports
on the combined use of PEG-V and LA-SRIF analogues describe the
use of PEG-V with either daily [10–12] or (twice) weekly administra-
tion of PEG-V [4–6,13]. However, the largest cohort of the reported
patients was treated using a (twice) weekly regime.
PEG-V, a GH receptor (GHR) antagonist, is a pegylated recombi-
nant analogue of GH with a substitution of glycine for alanine at
position 120 in GH-binding site II and 8 amino acid substitutions in
GH-binding site I, resulting in prevention of functional GHR signalling
and enhanced afﬁnity for the GHR [14]. To increase the half-life and
decrease immunogenicity the drugwas pegylated, resulting in a stable
42–46 kDa molecule[15,16].
In this review we will give an update of the available data on the
combined use of LA-SRIF and PEG-V in acromegaly patients and we
will discuss the beneﬁts and side effects of this combination therapy.
2. Efﬁcacy and dose reduction in combined treatment
PEG-V alone or combinedwith LA-SRIF analogues has a high efﬁcacy
of more than 90% in normalising IGF1. When used in combination with
LA-SRIF analogues theweeklymeandose of PEG-Vwas 77 mg [5,6]. This
is lower than during PEG-V mono-therapy with a weekly mean dose of
130 mg [7]. Data from the Acrostudy™, in which 23% of the patients
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ﬁve years efﬁcacy is around 60% with a weekly dose of 113 mg and
106 mg for controlled and uncontrolled, respectively [17]. Efﬁcacy rates
of the same magnitude were observed in the Co-administration of
lanreotideautogel and pegvisomant study [18]. The complicated design
of this study mainly focussed on PEG-V dose reduction and not on
optimal dose titration [18]. In a direct comparison between PEG-V alone
and combined treatment, no signiﬁcant difference in efﬁcacy was
observed [12], although this study suffered from a problem with the
IGF1 assay that had to be changed during the study period. This change
made an optimal dose titration based on IGF1 impossible [12]. Also,
the study was not designed to detect a dose difference between the
combined use of LA-SRIF and PEG-V mono-therapy [12].
The efﬁcacy of both treatment strategies is very high because of the
pharmacological properties of PEG-V that more or less guarantees
an efﬁcacy close to 100%, provided that patients are treated with the
proper dose. Therefore, the efﬁcacy comparisons between treatment
strategies which incorporate PEG-V are more or less meaningless,
unless compared with another medical intervention without PEG-V.
In another report, 2 patients who were controlled with high dose
PEG-V mono-therapy were converted to lanreotideautogel 120 mg
monthly and PEG-V weekly [9]. After conversion, a weekly dose
reduction of 80 and 150 mg could be achieved, without a change in
IGF1 levels [9]. Van der Lely et al., could observe a dose reduction of
51%, during co-administration of lanreotideautogel 120 mg [18]. Most
of these data suggest a signiﬁcant dose reduction during combined
treatment. However, the magnitude of the dose reduction can differ
signiﬁcantly between individual patients [9]. The implication of these
studies is that signiﬁcant dose-reductions can be achieved, especially
those patients requiring high-dose PEG-V mono-therapy in which
greatest gains are made when their dose can be reduced by 50%.
Needless to say, especially in the present market situation with the
high costs of PEG-V therapy, such dose reductions can have a signiﬁcant
impact on the cost-effectiveness of treatment.
2.1. The mechanism behind the combined use of LA-SRIF and PEG-V
That reduced doses of PEG-V can be used during combination
treatment with LA-SRIF might be partially explained by the 20%
increase in PEG-V serum levels compared with monotherapy [11,19].
GH levels increase during PEG-V treatment [7], but when PEG-V is
combined with LA-SRIF analogues, lower GH serum concentrations
are observed [11,19]. Additionally, SRIF analogues in rodent studies
showed that the number of GHRs expressed in the liver is reduced as a
result of decreased portal insulin concentration [20–22]. Therefore,
PEG-V (being a competitive GHR blocker) has less GH to competewith
and less GHRs to block. Also, LA-SRIF analogues can directly inhibit the
generation of IGF1 by hepatocytes [23]. These mechanisms combined
are the basis for the dose reduction observed during combined use of
LA-SRIF analogues and PEG-V [4–6,8,9,18,24].
During SRIF analogue mono-therapy, surgical tumour debulking
leads toahigher percentageof patients achievingbiochemical remission
with LA-SRIF analogues [25]. This is in contrast with LA-SRIF analogues
combinedwithPEG-V, inwhich thedoseof PEG-V required tonormalise
IGF1 did not differ between patients with primary medical treatment
and patients who previously underwent surgery (with or without RT)
[6]. The PEG-Vdose required tonormalise IGF1waspositively correlated
with baseline IGF1 levels, corrected for age and gender (r=0.48;
P=0.006) [6]. A similar result was observed during co-administration
of lanreotideautogel and PEG-V [18].
3. Quality of life aspects of the combination therapy
From a patient's perspective Quality of Life (QoL) is an important
parameter of disease control [13]. However, most clinicians focus
on the normalisation of both IGF1 and GH, which has been shownto correlate with normalisation of the elevated long-term mortality
rates of patients with acromegaly [26–30]. As already demonstrated,
biochemical normalisation does not completely relieve patients
from their symptoms [13,31]. These residual symptoms result in an
impaired QoL in patients with acromegaly [32–34]. The symptoms
and QoL can be quantiﬁed by the Patient-assessed Acromegaly
Symptom Questionnaire (PASQ™) [7] and the Acromegaly Quality
of Life Questionnaire (AcroQoL™) [35]. In a prospective, double blind,
placebo controlled, crossover trial QoL was assessed by AcroQoL and
the PASQ, with or without the addition of PEG-V, in acromegaly
patients with IGF1 levels within the age adjusted normal limits [13].
During the period of 16 weeks with 40 mg PEG-V weekly, QoL
improved in these so-called controlled acromegalic subjects, as
indicated by an increase in AcroQoL score total and AcroQoL score
physical dimension. This was accompanied by a reduction in the total
PASQ score and the single PASQ questions, perspiration, soft tissue
swelling and overall health status. Equally important, however, was
the observation that this improvement inQoL and signs and symptoms
was not accompanied by a signiﬁcant decrease in IGF1. No correlation
between IGF1 and improvement inQoLwas observed, but bodyweight
correlated with the improvement in the AcroQoL physical, although
the decrease of body weight was not signiﬁcant [13].
The mode of action of SRIF analogues might also explain why the
addition of PEG-V might improve QoL [13,36]. As already mentioned
above, SRIF analogue treatment reduces portal insulin concentrations
and, therefore, the number of available GHRs in the liver [22,36]. SRIF
analogues can also directly inhibit IGF1 production by hepatocytes
[23]. These mechanisms suggest that whereas the liver becomes
relatively resistant to GH during LA-SRIF analogue treatment, GH
actions in other organs and tissues of the body is still too high
[13,36,37]. Recently, in a Danish study, acromegaly patients with
normal IGF1 during LA-SRIF treatment still had elevated nadir GH
levels as comparedwith patients with a normal IGF1 after surgery and
had a reduced disease-speciﬁc health status [37]. Therefore, we
introduced the concept of ‘extra-hepatic acromegaly’ (Fig. 1A) [36].
One might expect that treatment of this 'extra hepatic acromegaly'
with low-dose, weekly PEG-V would improve the GH-dependent
signs and symptoms and the patient's QoL [13].
In mouse models, GH has tissue speciﬁc and temporal effects
independent of elevations in IGF1 serum levels. These tissue speciﬁc
effects in the absence of change in IGF1 serum levels are hard to study
in humans. In renal, adipose and skeletalmuscle tissue local GHactions
can be blocked with PEG-V without any change in serum IGF1 [38].
Treatment with PEG-V mono-therapy in acromegaly might lead
to a blockade of peripheral GH action without IGF1 decrease, which
we could call “hepatic acromegaly” (Fig. 1B) [36]. In the process of
normalising circulating IGF1 with PEG-V, peripheral tissues could
becomeGHdeﬁcient [36]. The improvement inQoL and the hypothesis
of the existence of 'extra-hepatic acromegaly', question the step-up
approach in which patients are only treated with PEG-Vwhen LA-SRIF
mono-therapy was not able to normalise IGF1 levels.
4. The effect of the combination therapy on glucose metabolism
The advantage of PEG-V over LA-SRIF analogue therapy with
respect to carbohydrate metabolism has been established in a study
of healthy volunteers [39]. In this study, the administration of PEG-V
did not inﬂuence fasting glucose, insulin levels or response to an oral
glucose load. This is opposed to the effects of octreotide treatment,
which augmented glucose levels and impaired insulin concentration
[39]. In long-term studies of acromegaly, combination treatment
with LA-SRIF analogues and weekly PEG-V decreased HbA1c levels in
patientswith diabetesmellitus, despite reduced dose requirements for
insulin or oral anti-diabetic medication [5,6,24]. This ﬁnding was not
conﬁrmed in a study by DeMarinis and co-workers [40]. Lower fasting
glucose levels were observed during combined treatment compared
Fig. 1. A. Effects of somatostatin analogues (SRIF) in SRIF sensitive acromegalic subjects. Red arrows indicate inhibitory effects; green arrows indicate stimulatory effects, while
thickness of arrow indicates level of inhibition. WAT=white adipose tissue; GH=growth hormone; IGF1=insulin-like growth factor 1. B. Effects of pegvisomant in acromegalic
subjects. Red arrows indicate inhibitory effects; green arrows indicate stimulatory effects, while thickness of arrow indicates level of inhibition. WAT = white adipose tissue;
GH = growth hormone; IGF1 = insulin-like growth factor 1 [36].
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levels were observed [11]. The co-administration of lanreotideautogel
and (twice) weekly PEG-V resulted in a decrease in mean fasting
insulin levels without a signiﬁcant change in other mean glucose
parameters in non-diabetic patients [18]. It seems that in the hierarchy
of its beneﬁcial effects on carbohydrate metabolism, PEG-V as mono-
therapy is superior to combined treatment [9]. However, combination
therapy is better than SRIF analogue mono-therapy [9].
5. Safety of the combined use of LA-SRIF and PEG-V
5.1. Pituitary tumour size during combination therapy
PEG-V is unable to prevent tumour growth, but in only a few cases
has clinically relevant tumour growth been reported [18,41]. In the
German Pegvisomant Observation Study, increased tumour-size wascarefully and systematically reviewed in over 300 patients. After this
thorough review, only 3 of the 8 initially reported patients had a real,
but minor, increase in tumour size after PEG-V was started [41]. In 3
other subjects, the initially reported increase in tumour-size had
already started before the initiation of PEG-V treatment [41]. In the
remaining 2 subjects a clear rebound in tumour-size was observed
after cessation of LA-SRIF analogues [41]. In another study, during
combination treatment no increase in tumour-sizewas observed in 99
patients [5]. Only in the study by Jorgensen and co-workers, in one of
11 patients investigated, an increase in tumour-size was observed
[11]. Some of the patients in this study received high dose long-acting
octreotide (30 mg every 2 weeks) prior to study entry. Moreover,
there were no data on a potential increase in tumour-size prior to
study entry and the study included a period in which patients were
treated with PEG-V mono-therapy as well. Therefore, it cannot
be excluded that a rebound phenomenon after discontinuation of
132 S.J.C.M.M. Neggers, A.J. van der Lely / Growth Hormone & IGF Research 21 (2011) 129–133LA-SRIF analogues was present as well. In 14 (19%) patients of the
remaining 74 (86 minus 12) patients with an assessable tumour size
in the study by Neggers and co-workers, tumour size decreased by
more than 20%, which is considered to be clinical signiﬁcant [24]. Two
patients in whom tumour shrinkage was observed had undergone
transsphenoidal surgery in the past and one had received radiother-
apy. The other 12 patients were on primary medical therapy. In none
of the 86 patients was an increase in tumour size observed [5,24].
5.2. Hepatotoxicity
A known side effect of PEG-V treatment is disturbance of liver
function, both during PEG-V mono-therapy and in combination
with SRIF analogues treatment. There are two well-known types
of hepatic enzyme disturbance: hepatocellular and cholestatic.
Cholestatic disturbances are most often related to treatment with
LA-SRIF analogues [5,6,10,42]. During LA-SRIF, a signiﬁcant proportion
of these patients have asymptomatic biliary stones, but active disease
is rare [42].
The described hepatocellular liver enzyme disturbances are
probably related to the use of PEG-V. The elevations in transaminase
levels are often mild and transient and occur within the ﬁrst year of
treatment [5,6,8,10,12,17]. The prevalence of elevated transaminases
ofmore than3 times the upper limit of normal (xULN), is higher during
combined treatment (15%) [5] than during PEG-V mono-therapy
(5.2%) [10]. In the most recent combination study, the prevalence
of elevated transaminases of more than 2 xULN were 11% [18]. The
difference between the German Pegvisomant Observational Study
[10,43], which resembles more closely every day practice, and the
more systematic follow-up of combined studies [4–6,9,13,18,24,44]
could explain the difference in prevalence of mostly transiently
elevated transaminases. If the intervals between out-patient clinic
visits are long enough, many episodes of transiently elevated trans-
aminases will go unnoticed. Of note, most patients who had elevated
levels of transaminases during combination treatment continued
taking PEG-V, whereas many of those who had such symptoms during
PEG-V mono-therapy did not [24]. Of the 33 patients reported
[5,10,12,24] with liver function abnormalities during combined
therapy, 3 patients suffered from biliary stones. Two of these patients
were treated with cholecystectomy [6,10] and subsequently only
one of these patients continued on combined therapy. Only 8 patients
on combined therapy, 5 with daily PEG-V [10,12] three with weekly
PEG-V [18,44], discontinued PEG-V treatment. One subject was re-
challenged with PEG-V alone and developed elevated transaminases
again [44]. Four patients, who previously had elevated transaminases,
during combined treatment re-developed liver dysfunction after re-
introduction of PEG-V after a PEG-V wash-out period of more than
4 months [5].
It seems that a speciﬁc group of acromegaly patients might have
an increased risk of developing these elevated transaminases with
a common polymorphism associated with Gilbert's syndrome,
UGT1A1*28 [45]. The incidence of homozygous and heterozygous
genotypes of UGT1A1*28 in acromegaly patientswas 54% [45]. In some
studies it has been reported that diabetic acromegaly patients have
a 2.3 times higher risk [5,6]. However, the impact of diabetes mellitus
on elevated transaminases over 3xULN seems to be less visible in
larger follow-up studies in cohorts of patients [5,24]. In other studies,
no relation between diabetes and elevated transaminases were
reported, however [10,18,43]. Neither (cumulative) PEG-V dose or
concomitant medication seems to matter either [5,6].
In the case of liver enzyme elevations, differentiation between the
involvement of mainly transaminases versus more cholestatic liver
enzyme disturbances is important. However, it is still advisable to
exclude cholelithiasis in all cases. If patients develop increases in liver
enzymes of more than 10xULN, we strongly suggest discontinuing
PEG-V treatment, especially in the case of a proven drug inducedhepatitis when one has also taken a biopsy of the liver of this par-
ticular patient [5]. After normalisation a re-challenge with PEG-V can
provoke elevated transaminases again [13].6. Conclusions
To date, cumulative data on the combined use of both long-acting
somatostatin analogues and PEG-V indicate that it is highly effective,
safe and well tolerated. It is questionable if combined treatment
should be reserved only for the so-called uncontrolled patient, since
“controlled” acromegalic patients in whom somatostatin analogue
treatment resulted in normalised serum IGF1 levels might beneﬁt
from the addition of PEG-V as well. This proposed change in paradigm
is related to the suggested existence of extra-hepatic acromegaly
in these “controlled” patients under LA-SRIF treatment. Combined
treatment can still induce tumour shrinkage as observed during long-
acting somatostatin analogue mono-therapy and has the same
efﬁcacy as PEG-V mono-therapy, because PEG-V itself already has
a dose dependent efﬁcacy that enables normalisation of IGF1 in
virtually all patients. Combined treatment, however, shows compa-
rable efﬁcacy rates with signiﬁcantly lower cumulative dosages of
PEG-V. Therefore, combined treatment can signiﬁcantly decrease
costs for at least a proportion of acromegalic patients, provided that
they are partially resistant to long-acting somatostatin analogues.
Frequent assessment of liver enzymes is mandatory, as indicated in
the package insert of PEG-V.References
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